Underproduction of endogenous erythropoietin by atrophic renal cortex is one of the major causes of anemia in CKD patients, and treatment with erythropoiesis-stimulating agents (ESAs) increases Hb effectively1. Here, GSTM1 is linked to chronic kidney disease.